| 1. |
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone,
metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. |
| 2. |
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of
macrovascular events in patients with type 2 diabetes in the PROactive Study
(PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised
controlled trial. Lancet 2005;366:1279-89. |
| 3. |
Vestergaard P. Discrepancies in bone mineral density and fracture risk in
patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int
2007;18:427-44. |
| 4. |
Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int
2007. |
| 5. |
Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and
bone loss in older diabetic adults. J Clin Endocrinol Metab
2006;91:3349-54. |
| 6. |
Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated
receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral
density in healthy postmenopausal women: a randomized, controlled trial. J Clin
Endocrinol Metab 2007;92:1305-10. |
| 7. |
Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener
Demirag N. Rosiglitazone decreases serum bone-specific alkaline phosphatase
activity in postmenopausal diabetic women. J Clin Endocrinol Metab
2007;92:3523-30. |
| 8. |
Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone
mineral density in type 2 diabetic men. Diabetes Care 2007;30:1574-6. |
|
|
